Mode
Text Size
Log in / Sign up

Polygenic risk scores validate IL-1 signaling role in childhood asthma, supporting IL1R1 antagonist repurposingNew data links specific proteins to asthma risk in children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider IL1R1 antagonists as a potential repurposing candidate for asthma based on genetic and proteomic evidence.

This meta-analysis examined the validity of externally derived asthma polygenic risk scores (GBMI-PRS) in children from two family-based cohorts (GACRS and CAMP). The primary outcome was the validity of the PRS and its association with clinical phenotypes. The analysis provided robust evidence supporting the validity of the PRS (p=10^-24). Additionally, 13 of 21 clinical traits (62%) were significantly associated with the GBMI-PRS after multiple-testing correction.

Integrative proteomic analysis implicated IL-1 signaling in the etiology of asthma, with protein abundance prediction models for IL1R1. This finding reinforces the candidacy of IL1R1 antagonists for drug repurposing in asthma. However, the authors caution that drug repurposing remains a candidacy, not a confirmed clinical outcome.

The study did not report sample size, follow-up duration, or safety data. Limitations were not explicitly stated. The results are based on association, not causation, and further research is needed to confirm clinical utility.

How this fits prior evidence

This meta-analysis extends prior findings on asthma management by providing genetic and proteomic evidence supporting IL-1 signaling as a therapeutic target. Prior coverage noted that structured physical activity improves FEV1% predicted and quality of life, and system-level strategies improve asthma care equity. The current results add a molecular rationale for targeting IL1R1, potentially complementing these strategies. However, unlike the casirivimab plus imdevimab trial which showed reduced hospitalization risk, this analysis does not test a specific intervention but supports drug repurposing candidacy.

Managing asthma in children is often complicated because the condition looks different in every child. New research looked at how genetics and proteins work together to shape these symptoms. The study focused on two groups of children to see if specific genetic scores could accurately predict clinical traits like lung function and allergy markers.

The results showed that a specific genetic risk score was highly accurate. This tool linked to many different parts of the disease, including how well a child can breathe and their levels of certain proteins. Specifically, the researchers found that IL-1 signaling plays a role in why asthma develops in the first place.

While these findings are promising, it is important to remember that this research is about identifying targets for future medicine. The study suggests that certain drugs currently used for other issues might eventually be repurposed to treat asthma, but this is still a candidate path rather than a confirmed treatment.

What this means for you:
Genetic markers and protein levels help identify specific pathways that contribute to childhood asthma.

Common questions

What did the study find about the causes of asthma?

The research used a proteomic analysis, which looks at protein levels in the body. This analysis showed that IL-1 signaling is involved in the development of asthma. By identifying these specific proteins, researchers can better understand why the condition starts in children.

How accurate were the genetic markers used?

The study found robust evidence supporting the validity of the genetic risk scores used. These scores were linked to 13 out of 21 different clinical traits, including lung function and allergy markers, showing a strong connection between genetics and how asthma presents in children.

Does this mean there is a new treatment for kids with asthma?

Not yet. The study suggests that certain medications could be repurposed to treat asthma because of the protein signals found. However, this is currently a candidacy for future research and not a confirmed clinical outcome or a new available treatment.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Despite its high prevalence and the discovery of hundreds of genetic associations, the genetic determinants and heterogeneous manifestations of asthma remain incompletely understood. Incorporating polygenic risk scores (PRS) into asthma research offers a powerful approach to quantify inherited susceptibility, refine risk profiles, and advance mechanistic understanding of disease development. For this study, we leveraged whole-genome sequencing (WGS) data from two family-based cohorts of childhood asthma - the Genetics of Asthma in Costa Rica Study (GACRS) and the Childhood Asthma Management Program (CAMP) - to examine the transmission profiles of externally derived asthma PRS and their associations with clinical phenotypes in children with asthma. To further elucidate molecular mechanisms, we integrated large-scale external genome-wide association study (GWAS) summary statistics and genetic prediction models of protein abundance in a two-step proteome-wide association study (PWAS) of asthma. Our findings provide robust evidence supporting the validity of externally derived asthma PRS (asthma PRS association p-value p={10}^{-24} [GACRS and CAMP trios combined] for the Global Biobank Meta-analysis Initiative [GBMI]) and reveal consistent associations with spirometry measures and atopy markers across both studies, as 13 of 21 traits (62%) were significantly associated with the GBMI-PRS in the meta-analysis after multiple-testing correction. Moreover, the results of the integrative proteomic analysis implicate IL-1 signaling in the etiology of asthma, reinforcing the candidacy of IL1R1 antagonists for drug repurposing.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.